CAR-T Treatments

Bristol Myers Squibb Buys Orbital Therapeutics for $1.5 Billion to Push In Vivo CAR‑T Into Autoimmune Care

The deal signals a pivot toward in‑body cell reprogramming for autoimmune disease.